The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Novo Nordisk's first-quarter results beat consensus expectations, driven by a strong launch of the Wegovy pill. Despite this performance, Citi raised its target price for the stock to DKK290 while maintaining a neutral rating. According to reports, the bank cut its 2026 sales estimates by 4% and operating income projections by 7%, citing concerns over portfolio price erosion in the medium term.
Sign in to access this content
Sign InCiti's caution comes amid intensifying competition in the obesity drug market, particularly from Eli Lilly, which recently reported robust sales growth for its Zepbound treatment. Per market data, major pharmaceutical stocks have faced volatility as regulatory pressure on drug pricing in the U.S. increases. Previous earnings reports indicate that Novo Nordisk has invested heavily in expanding production capacity to meet global demand, which could pressure margins if price erosion persists.
Investors are monitoring Novo Nordisk (NVO) price levels, which stood at $124.50 at close May 12, 2026. Looking at the economic calendar, there are no direct pharmaceutical sector catalysts in the next seven days, though speeches from Fed officials like Kashkari and Goolsbee may influence risk appetite in growth sectors. Traders should watch support levels near last week's lows to gauge how the market absorbs Citi's cautious outlook.